DSM-Firmenich completed buyback and DSM-Firmenich stock gains 2.94 percent

Published on 10/13/2026 at 09:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The cancellation covers 6,488,446 shares. DSM-Firmenich stock was EUR 102.55 on October 13, 2026, 1.16 percent below its EUR 103.75 high.

Key points in brief

DSM-Firmenich completed its EUR 540.00 million share repurchase program on October 1, 2026.
The company plans to cancel 6,488,446 shares by the end of the first quarter of 2027.
DSM-Firmenich stock traded at EUR 102.55 at Lang & Schwarz on October 13, 2026, up 2.94 percent versus the Xetra close of EUR 99.62 on October 12, 2026.
Second-quarter 2026 revenue was EUR 4.66 billion and net income was EUR 212.00 million.

Schwarzweiß-Reportagefoto eines Ingenieurs an großen Bioreaktoren — dsm-firmenich AG (ISIN CH1216478797) fertigt Vitamine und Enzyme in industriellen Bioreaktoren, dokumentarisch schwarzweiß fotografiert, Illustration mit AI erstellt.

DSM-Firmenich (CH1216478797) traded at EUR 102.55 at Lang & Schwarz on October 13, 2026 at 9:49 a.m. CEST, up 2.94 percent versus the Xetra close of EUR 99.62 on October 12, 2026. The company had completed its EUR 540.00 million share repurchase program on October 1, 2026, according to dsm-firmenich.

Buyback reduces future share count

The program repurchased 7,169,147 shares for a total consideration of EUR 540.00 million at an average price of EUR 75.32, the company said in its October 1, 2026 release. Of those shares, 6,488,446 were earmarked for capital reduction, while 680,701 covered share-based compensation commitments.

The company plans to cancel the 6,488,446 shares by the end of the first quarter of 2027. That would reduce issued shares from 253,626,947 to 247,138,501, a planned reduction of 2.60 percent, according to dsm-firmenich.

What does the latest quarter show?

In the second quarter of 2026, revenue reached EUR 4.66 billion and net income was EUR 212.00 million, according to the standardized financial statement for the period ended June 30, 2026. The revenue figure was higher than the EUR 2.33 billion reported for the first quarter of 2026, while net income increased from EUR 108.00 million to EUR 212.00 million.

The latest half-year context adds an operating measure. De Belegger reported that first-half 2026 adjusted EBITDA was EUR 900.00 million, equal to a 19.30 percent margin, while comparable revenue growth reached 5.00 percent. The same report put second-quarter comparable growth at 6.00 percent.

Analyst target remains close to the price

BNP Paribas downgraded DSM-Firmenich from Outperform to Neutral on October 2, 2026 and set a EUR 100.00 price target, according to Markets Insider. That target is EUR 2.55 below the Lang & Schwarz price, so the rating change provides a counterweight to the buyback arithmetic.

Three dated capital milestones

On March 12, 2026, DSM-Firmenich started the EUR 540.00 million repurchase program. On July 30, 2026, the company reported first-half revenue of EUR 4.66 billion and adjusted EBITDA of EUR 900.00 million. On October 1, 2026, it completed the buyback and disclosed the planned 2.60 percent capital reduction, according to the company release.

Next shareholder date

A special shareholders meeting is scheduled for October 19, 2026, according to Simply Wall St. The meeting gives shareholders a dated point for assessing the capital reduction plan before the end of the first quarter of 2027.

Stock trades near its yearly high

At EUR 102.55, DSM-Firmenich stock was EUR 1.20 below its EUR 103.75 52-week high on October 13, 2026. The current market capitalization was EUR 25.3 billion, while the primary Euronext Amsterdam quotation showed a 52-week range of EUR 55.22 to EUR 103.75.

The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.